Addressing Female Sexual Function after Cancer by Internists and Primary Care Providers

Journal of Sexual Medicine

Volumn 10, Issue SUPPL., 2013, Pages 112-119

  Bober, Sharon L ^a,b   Carter, Jeanne ^c   Falk, Sandy ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Female sexual function; Primary care; Survivorship

Indexed keywords

ALPHA TOCOPHEROL; ESTROGEN; HYALURONIC ACID; LUBRICATING AGENT; POLYCARBOPHIL; TAMOXIFEN;

BREAST CANCER; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL EFFECTIVENESS; FEMALE SEXUAL DYSFUNCTION; GENERAL PRACTITIONER; GYNECOLOGIC CANCER; HUMAN; INTEGRATIVE MEDICINE; INTERNIST; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL HEALTH; SEXUALITY; VAGINA ATROPHY; VAGINAL DRYNESS;

EID: 84873429786     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12027     Document Type: Article

References (61)

1. Grunfeld E. Primary care physicians and oncologists are players on the same team. J Clin Oncol 2008;26:2246-7.
2. Institute of Medicine, National Research Council of the National Academies. From cancer patient to cancer survivor: Lost in transition. In: Hewitt M, Greenfield S, Stovall E, eds. Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: The National Academies Press; 2006:1-15.
3. Robinson JW. Sexuality and cancer. Breaking the silence. Aust Fam Physician 1998;27:45-7.
4. Andersen BL, Woods XA, Copeland LJ. Sexual self-schema and sexual morbidity among gynecologic cancer survivors. J Consult Clin Psychol 1997;65:221-9.
5. Schover LR. Premature ovarian failure and its consequences: Vasomotor symptoms, sexuality, and fertility. J Clin Oncol 2008;26:753-8.
6. Park ER, Bober SL, Campbell EG, Recklitis CJ, Kutner JS, Diller L. General internist communication about sexual function with cancer survivors. J Gen Intern Med 2009;24(suppl 2):S407-11.
7. Hordern AJ, Currow DC. A patient-centred approach to sexuality in the face of life-limiting illness. Med J Aust 2003;179:S8-11.
8. Flynn KE, Reese JB, Jeffery DD, Abernethy AP, Lin L, Shelby RA, Porter LS, Dombeck CB, Weinfurt KP. Patient experiences with communication about sex during and after treatment for cancer. Psychooncology 2012;21:594-601.
9. Bober SL, Recklitis CJ, Campbell EG, Park ER, Kutner JS, Najita JS, Diller L. Caring for cancer survivors: A survey of primary care physicians. Cancer 2009;115:4409-18.
10. Fiore MC, Bailey WC, Cohen SJ. Treating tobacco use and dependence: Clinical practice guideline. Rockville: U.S. Department of Health and Human Services, U.S. Public Health Service; 2000.
11. Park ER, Norris RL, Bober SL. Sexual health communication during cancer care: Barriers and recommendations. Cancer J 2009;15:74-7.
12. Tsimtsiou Z, Hatzimouratidis K, Nakopoulou E, Kyrana E, Salpigidis G, Hatzichristou D. Predictors of physicians' involvement in addressing sexual health issues. J Sex Med 2006;3:583-8.
13. Abdolrasulnia M, Shewchuk RM, Roepke N, Granstaff US, Dean J, Foster JA, Goldstein AT, Casebeer L. Management of female sexual problems: Perceived barriers, practice patterns, and confidence among primary care physicians and gynecologists. J Sex Med 2010;7:2499-508.
14. Stead ML, Brown JM, Fallowfield L, Selby P. Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. Br J Cancer 2003;88:666-71.
15. Tsai YF. Nurses' facilitators and barriers for taking a sexual history in Taiwan. Appl Nurs Res 2004;17:257-64.
16. Hordern A, Street A. Issues of intimacy and sexuality in the face of cancer: The patient perspective. Cancer Nurs 2007;30:E11-8.
17. Bourgeois-Law G, Lotocki R. Sexuality and gynecological cancer: A needs assessment. Can J Hum Sex 1999;8:231-40.
18. Feldman-Stewart D, Brundage MD, Hayter C, Groome P, Nickel JC, Downes H, Mackillop WJ. What questions do patients with curable prostate cancer want answered? Med Decis Making 2000;20:7-19.
19. Varela VS, Nelson CJ, Bober SL. Sexual problems. In: DeVita VTJ, Lawrence TS, Rosenberg SA, eds. Cancer: Principles & practice of oncology. 9th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:2456-66.
20. Abbott-Anderson K, Kwekkeboom KL. A systematic review of sexual concerns reported by gynecological cancer survivors. Gynecol Oncol 2011;124:477-89.
21. Hendren SK, O'Connor BI, Liu M, Asano T, Cohen Z, Swallow CJ, Macrae HM, Gryfe R, McLeod RS. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg 2005;242:212-23.
22. Hammond CT, Beckjord EB, Arora NK, Bellizzi KM, Jeffery DD, Aziz NM. Non-Hodgkin's lymphoma survivors' fertility and sexual function-related information needs. Fertil Steril 2007;90:1256-8.
23. Marwick C. Survey says patients expect little physician help on sex. JAMA 1999;281:2173-4.
24. Scott JL, Kayser K. A review of couple-based interventions for enhancing women's sexual adjustment and body image after cancer. Cancer J 2009;15:48-56.
25. World Health Organization. Sexual and reproductive health core competencies in primary care: Attitudes, knowledge, ethics, human rights, leadership, management, teamwork, community work, education, counselling, clinical settings, service, provision. Geneva, Switzerland: WHO Press; 2011.
26. Hordern A. Intimacy and sexuality after cancer: A critical review of the literature. Cancer Nurs 2008;31:E9-17.
27. Annon JS. The PLISSIT model: A proposed conceptual scheme for the behavioral treatment of sexual problems. J Sex Educ Ther 1976;2:1-15.
28. Schover LR. Sexuality and fertility after cancer. Hematology Am Soc Hematol Educ Program 2005;2005:523-7.
29. Sadovsky R, Basson R, Krychman M, Morales AM, Schover L, Wang R, Incrocci L. Cancer and sexual problems. J Sex Med 2010;7:349-73.
30. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: Changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847-53.
31. Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 1999;17:1488-92.
32. Boccardo F, Bruzzi P, Rubagotti A, Nicolò GU, Rosso R. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 1981;38:281-5.
33. Schover LR. Androgen therapy for loss of desire in women: Is the benefit worth the breast cancer risk? Fertil Steril 2008;90:129-40.
34. Karabulut N, Erci B. Sexual desire and satisfaction in sexual life affecting factors in breast cancer survivors after mastectomy. J Psychosoc Oncol 2009;27:332-43.
35. Krychman ML, Katz A. Breast cancer and sexuality: Multi-modal treatment options. J Sex Med 2012;9:5-13; quiz 4-5.
36. Robson M, Hensley M, Barakat R, Brown C, Chi D, Poynor E, Offit K. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol 2003;89:281-7.
37. Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 2005;23:6890-8.
38. European Working Group on HIV Infection in Female Prostitutes. HIV infection in European female sex workers: Epidemiological link with use of petroleum-based lubricants. AIDS 1993;7:401-8.
39. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259-63.
40. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-80.
41. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland KM Jr, Law M, Windschitl HE, Kaur JS, Ellison N. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15:969-73.
42. Caswell M, Kane M. Comparison of the moisturization efficacy of two vaginal moisturizers: Pectin versus polycarbophil technologies. J Cosmet Sci 2002;53:81-7.
43. Costantino D, Guaraldi C. Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: An open, non-controlled clinical trial. Eur Rev Med Pharmacol Sci 2008;12:411-6.
44. Ekin M, Yasar L, Savan K, Temur M, Uhri M, Gencer I, Kivanç E. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Arch Gynecol Obstet 2011;283:539-43.
45. Rosenbaum TY. Pelvic floor involvement in male and female sexual dysfunction and the role of pelvic floor rehabilitation in treatment: A literature review. J Sex Med 2007;4:4-13.
46. Nunes JM, Feldner PCJ, Castro RA, Nader HB, Sartori MG, Girão MJ. Uterine prolapse: Evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric 2011;14:121-5. Epub 2010 Aug 7.
47. Tea MKM, Priemer V, Kubista E. Aktuelles: Wirksamkeit und sicherheit von Hyaluron-saure-Zapfchen (Cikatridina[R]) beider Behandlung hormon-oder chemotherapieinduzierter vaginaler Attrophie bie Mammakarzinom patientinnen. fur Fertilitat und Reproduktion 2006;16:17-9.
48. Markowska J, Madry R, Markowska A. The effect of hyaluronic acid (Cicatridine) on healing and regeneration of the uterine cervix and vagina and vulvar dystrophy therapy. Eur J Gynaecol Oncol 2011;32:65-8.
49. Schroder M, Mell LK, Hurteau JA, Collins YC, Rotmensch J, Waggoner SE, Yamada SD, Small W Jr, Mundt AJ. Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients. Int J Radiat Oncol Biol Phys 2005;61:1078-86.
50. Billups KL, Berman L, Berman J, Metz ME, Glennon ME, Goldstein I. A new non-pharmacological vacuum therapy for female sexual dysfunction. J Sex Marital Ther 2001;27:435-41.
51. Schover LR. Sexuality and fertility after cancer. New York: John Wiley & Sons; 1997.
52. Goldfinger C, Pukall CF, Gentilcore-Saulnier E, McLean L, Chamberlain S. A prospective study of pelvic floor physical therapy: Pain and psychosexual outcomes in provoked vestibulodynia. J Sex Med 2009;6:1955-68.
53. Tu FF, Holt J, Gonzales J, Fitzgerald CM. Physical therapy evaluation of patients with chronic pelvic pain: A controlled study. Am J Obstet Gynecol 2008;198:272 e1-7.
54. Lowenstein L, Gruenwald I, Gartman I, Vardi Y. Can stronger pelvic muscle floor improve sexual function? Int Urogynecol J 2010;21:553-6.
55. Denton AS, Maher EJ. Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy. Cochrane Database Syst Rev 2003;(1):CD003750.
56. Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev 2010;(9):CD007291.
57. Henriksson L, Stjernquist M, Boquist L, Alander U, Selinus I. A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol 1994;171:624-32.
58. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency-A pharmacokinetic and pharmacodynamic study. Maturitas 1992;15:121-7.
59. van der Laak JA, de Bie LM, de Leeuw H, de Wilde PC, Hanselaar AG. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: Cytomorphology versus computerised cytometry. J Clin Pathol 2002;55:446-51.
60. Decruze SB, Guthrie D, Magnani R. Prevention of vaginal stenosis in patients following vaginal brachytherapy. Clin Oncol (R Coll Radiol) 1999;11:46-8.
61. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053-60.